SCHEMBL2959065

SCHEMBL2959065

CC(C)(C)n1nc(-c2ccc3[nH]c(Cc4ccccc4)nc3c2)c2c(N)ncnc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 12/20 0.60
▸ ABL1 P00519 7/20 0.60
▸ PIK3CD O00329 1/20 0.60
▸ PIK3CA P42336 1/20 0.60
▸ PIK3CB P42338 1/20 0.60
▸ PIK3CG P48736 1/20 0.60
▸ PRKDC P78527 1/20 0.60
▸ RET P07949 8/20 0.58
▸ KDR P35968 8/20 0.58
▸ EGFR P00533 2/20 0.55
▸ ERBB2 P04626 2/20 0.55
▸ IGF1R P08069 1/20 0.55
▸ KDM4E B2RXH2 1/20 0.54
▸ PLK4 O00444 1/20 0.54
▸ RIPK2 O43353 1/20 0.54
▸ ROCK2 O75116 1/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ MAP4K4 O95819 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960985 0.82 IGF1R (0.68) SRCEGFRERBB2IGF1RLCK
SCHEMBL2967251 0.82 SRC (0.54) SRCABL1RETKDREGFR
SCHEMBL2958098 0.81 IGF1R (0.69) EGFRERBB2IGF1R
SCHEMBL2965098 0.81 PIK3CD (0.51) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL2966913 0.81 RET (0.60) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL2967474 0.81 IGF1R (0.76) EGFRERBB2IGF1R
SCHEMBL2958781 0.79 IGF1R (0.68) EGFRERBB2IGF1R
SCHEMBL2959892 0.79 IGF1R (0.68) EGFRERBB2IGF1R
SCHEMBL2958786 0.79 IGF1R (0.68) EGFRERBB2IGF1R
SCHEMBL2955758 0.79 IGF1R (0.64) SRCRETKDREGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 SRC 106/4885ABL1 60/4885PIK3CD 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback